OBJECTIVE: Describe central line-associated bloodstream infection (CLA-BSI) epidemiology in pediatric intensive care units (PICUs). DESIGN: Descriptive study (29 PICUs); cohort study (18 PICUs). SETTING: PICUs in a national improvement collaborative. PATIENTS/PARTICIPANTS: Patients admitted October 2006 to December 2007 with 1 or more central lines. METHODS: CLA-BSIs were prospectively identified using the National Healthcare Safety Network definition and then readjudicated using the revised 2008 definition. Risk factors for CLA-BSI were examined using age-adjusted, time-varying Cox proportional hazards models. RESULTS: In the descriptive study, the CLA-BSI incidence was 3.1/1,000 central line-days; readjudication with the revised definition resulted in a 17% decrease. In the cohort study, the readjudicated incidence was 2.0/1,000 central line-days. Ninety-nine percent of patients were CLA-BSI-free through day 7, after which the daily risk of CLA-BSI doubled to 0.27% per day. Compared with patients with respiratory diagnoses (most prevalent category), CLA-BSI risk was higher in patients with gastrointestinal diagnoses (hazard ratio [HR], 2.7 [95% confidence interval {CI}, 1.43-5.16]; P < .002 ) and oncologic diagnoses (HR, 2.6 [CI, 1.06-6.45]; P = .037). Among all patients, including those with more than 1 central line, CLA-BSI risk was lower among patients with a central line inserted in the jugular vein (HR, 0.43 [CI, 0.30-0.95]; [P < .03). CONCLUSIONS: The 2008 CLA-BSI definition change decreased the measured incidence. The daily CLA-BSI risk was very low in patients during the first 7 days of catheterization but doubled thereafter. The risk of CLA-BSI was lower in patients with lines inserted in the jugular vein and higher in patients with gastrointestinal and oncologic diagnoses. These patients are target populations for additional study and intervention.
OBJECTIVE: Describe central line-associated bloodstream infection (CLA-BSI) epidemiology in pediatric intensive care units (PICUs). DESIGN: Descriptive study (29 PICUs); cohort study (18 PICUs). SETTING: PICUs in a national improvement collaborative. PATIENTS/PARTICIPANTS: Patients admitted October 2006 to December 2007 with 1 or more central lines. METHODS: CLA-BSIs were prospectively identified using the National Healthcare Safety Network definition and then readjudicated using the revised 2008 definition. Risk factors for CLA-BSI were examined using age-adjusted, time-varying Cox proportional hazards models. RESULTS: In the descriptive study, the CLA-BSI incidence was 3.1/1,000 central line-days; readjudication with the revised definition resulted in a 17% decrease. In the cohort study, the readjudicated incidence was 2.0/1,000 central line-days. Ninety-nine percent of patients were CLA-BSI-free through day 7, after which the daily risk of CLA-BSI doubled to 0.27% per day. Compared with patients with respiratory diagnoses (most prevalent category), CLA-BSI risk was higher in patients with gastrointestinal diagnoses (hazard ratio [HR], 2.7 [95% confidence interval {CI}, 1.43-5.16]; P < .002 ) and oncologic diagnoses (HR, 2.6 [CI, 1.06-6.45]; P = .037). Among all patients, including those with more than 1 central line, CLA-BSI risk was lower among patients with a central line inserted in the jugular vein (HR, 0.43 [CI, 0.30-0.95]; [P < .03). CONCLUSIONS: The 2008 CLA-BSI definition change decreased the measured incidence. The daily CLA-BSI risk was very low in patients during the first 7 days of catheterization but doubled thereafter. The risk of CLA-BSI was lower in patients with lines inserted in the jugular vein and higher in patients with gastrointestinal and oncologic diagnoses. These patients are target populations for additional study and intervention.
Authors: Susan E Coffin; Sarah B Klieger; Christopher Duggan; W Charles Huskins; Aaron M Milstone; Gail Potter-Bynoe; Bram Raphael; Thomas J Sandora; Xiaoyan Song; Danielle M Zerr; Grace M Lee Journal: Infect Control Hosp Epidemiol Date: 2014-10-02 Impact factor: 3.254
Authors: Michael L Rinke; Aaron M Milstone; Allen R Chen; Kara Mirski; David G Bundy; Elizabeth Colantuoni; Miriana Pehar; Cynthia Herpst; Marlene R Miller Journal: Pediatr Blood Cancer Date: 2013-07-23 Impact factor: 3.167
Authors: Sung W Choi; Lawrence Chang; David A Hanauer; Jacqueline Shaffer-Hartman; Daniel Teitelbaum; Ian Lewis; Alex Blackwood; Nur Akcasu; Janell Steel; Joy Christensen; Matthew F Niedner Journal: Pediatr Blood Cancer Date: 2012-04-22 Impact factor: 3.167
Authors: Jeffrey D Edwards; Carolyn T Herzig; Hangsheng Liu; Monika Pogorzelska-Maziarz; Philip Zachariah; Andrew W Dick; Lisa Saiman; Patricia W Stone; E Yoko Furuya Journal: Am J Infect Control Date: 2015-05-01 Impact factor: 2.918
Authors: Aaron M Milstone; Alexis Elward; Xiaoyan Song; Danielle M Zerr; Rachel Orscheln; Kathleen Speck; Daniel Obeng; Nicholas G Reich; Susan E Coffin; Trish M Perl Journal: Lancet Date: 2013-01-28 Impact factor: 79.321
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-02-14 Impact factor: 17.440
Authors: Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann Journal: GMS Hyg Infect Control Date: 2016-05-12